A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Trilostane
Epicaptopril
The risk or severity of hypertension can be increased when Epicaptopril is combined with Indacaterol.
Trilostane
Tiaprofenic acid
The risk or severity of hypertension can be increased when Tiaprofenic acid is combined with Indacaterol.
Trilostane
Phendimetrazine
The risk or severity of hypertension can be increased when Phendimetrazine is combined with Indacaterol.
Trilostane
Chlorphentermine
The risk or severity of hypertension can be increased when Chlorphentermine is combined with Indacaterol.
Trilostane
Tenamfetamine
The risk or severity of hypertension can be increased when Tenamfetamine is combined with Indacaterol.
Trilostane
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of hypertension can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Indacaterol.
Trilostane
4-Methoxyamphetamine
The risk or severity of hypertension can be increased when 4-Methoxyamphetamine is combined with Indacaterol.
Trilostane
2,5-Dimethoxy-4-ethylamphetamine
The risk or severity of hypertension can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Indacaterol.
Trilostane
MMDA
The risk or severity of hypertension can be increased when MMDA is combined with Indacaterol.
Trilostane
Antrafenine
The risk or severity of hypertension can be increased when Antrafenine is combined with Indacaterol.
Trilostane
Choline magnesium trisalicylate
The risk or severity of hypertension can be increased when Choline magnesium trisalicylate is combined with Indacaterol.
Trilostane
Salsalate
The risk or severity of hypertension can be increased when Salsalate is combined with Indacaterol.
Trilostane
Magnesium salicylate
The risk or severity of hypertension can be increased when Magnesium salicylate is combined with Indacaterol.
Trilostane
Mephentermine
The risk or severity of hypertension can be increased when Mephentermine is combined with Indacaterol.
Trilostane
Lumiracoxib
The risk or severity of hypertension can be increased when Lumiracoxib is combined with Indacaterol.
Trilostane
Olsalazine
The risk or severity of hypertension can be increased when Olsalazine is combined with Indacaterol.
Trilostane
Rescinnamine
The risk or severity of hypertension can be increased when Rescinnamine is combined with Indacaterol.
Trilostane
Levamlodipine
Indacaterol may decrease the antihypertensive activities of Levamlodipine.
Trilostane
Candesartan
Indacaterol may decrease the antihypertensive activities of Candesartan.
Trilostane
Naftopidil
Indacaterol may decrease the antihypertensive activities of Naftopidil.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3